DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy

Yusuke Kaida, Kei Fukami, Takanori Matsui, Yuichiro Higashimoto, Yuri Nishino, Nana Obara, Yosuke Nakayama, Ryotaro Ando, Maki Toyonaga, Seiji Ueda, Masayoshi Takeuchi, Hiroyoshi Inoue, Seiya Okuda, Shoichi Yamagishi

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Advanced glycation end products (AGEs) and their receptor (RAGE) play a role in diabetic nephropathy. We screened DNA aptamer directed against AGEs (AGEs-aptamer) in vitro and examined its effects on renal injury in KKAy/Ta mice, an animal model of type 2 diabetes. Eight-week-old male KKAy/Ta or C57BL/6J mice received continuous intraperitoneal infusion of AGEs-or control-aptamer for 8 weeks. AGEs-aptamer was detected and its level was increased in the kidney for at least 7 days. The elimination half-lives of AGEs-aptamer in the kidney were about 7 days. Compared with those in C57BL/6J mice, glomerular AGEs levels were significantly increased in KKAy/Ta mice, which were blocked by AGEs-aptamer. Urinary albumin and 8-hydroxy-29-deoxy-guanosine levels were increased, and glomerular hypertrophy and enhanced extracellular matrix accumulation were observed in KKAy/Ta mice, all of which were prevented by AGEs-aptamer. Moreover, AGEs-aptamer significantly reduced gene expression of RAGE, monocyte chemoattractant protein-1, connective tissue growth factor, and type IV collagen both in the kidney of KKAy/Ta mice and in AGE-exposed human cultured mesangial cells. Our present data suggest that continuous administration of AGEs-aptamer could protect against experimental diabetic nephropathy by blocking the AGEs-RAGE axis and may be a feasible and promising therapeutic strategy for the treatment of diabetic nephropathy.

Original languageEnglish
Pages (from-to)3241-3250
Number of pages10
JournalDiabetes
Volume62
Issue number9
DOIs
Publication statusPublished - 2013 Sep

Fingerprint

Nucleotide Aptamers
Diabetic Nephropathies
Kidney
Inbred C57BL Mouse
Parenteral Infusions
Connective Tissue Growth Factor
Advanced Glycosylation End Products
Mesangial Cells
Guanosine
Chemokine CCL2
Type 2 Diabetes Mellitus
Hypertrophy
Extracellular Matrix
Albumins
Cultured Cells
Collagen
Animal Models
Gene Expression
Wounds and Injuries
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Kaida, Y., Fukami, K., Matsui, T., Higashimoto, Y., Nishino, Y., Obara, N., ... Yamagishi, S. (2013). DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy. Diabetes, 62(9), 3241-3250. https://doi.org/10.2337/db12-1608

DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy. / Kaida, Yusuke; Fukami, Kei; Matsui, Takanori; Higashimoto, Yuichiro; Nishino, Yuri; Obara, Nana; Nakayama, Yosuke; Ando, Ryotaro; Toyonaga, Maki; Ueda, Seiji; Takeuchi, Masayoshi; Inoue, Hiroyoshi; Okuda, Seiya; Yamagishi, Shoichi.

In: Diabetes, Vol. 62, No. 9, 09.2013, p. 3241-3250.

Research output: Contribution to journalArticle

Kaida, Y, Fukami, K, Matsui, T, Higashimoto, Y, Nishino, Y, Obara, N, Nakayama, Y, Ando, R, Toyonaga, M, Ueda, S, Takeuchi, M, Inoue, H, Okuda, S & Yamagishi, S 2013, 'DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy', Diabetes, vol. 62, no. 9, pp. 3241-3250. https://doi.org/10.2337/db12-1608
Kaida Y, Fukami K, Matsui T, Higashimoto Y, Nishino Y, Obara N et al. DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy. Diabetes. 2013 Sep;62(9):3241-3250. https://doi.org/10.2337/db12-1608
Kaida, Yusuke ; Fukami, Kei ; Matsui, Takanori ; Higashimoto, Yuichiro ; Nishino, Yuri ; Obara, Nana ; Nakayama, Yosuke ; Ando, Ryotaro ; Toyonaga, Maki ; Ueda, Seiji ; Takeuchi, Masayoshi ; Inoue, Hiroyoshi ; Okuda, Seiya ; Yamagishi, Shoichi. / DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy. In: Diabetes. 2013 ; Vol. 62, No. 9. pp. 3241-3250.
@article{3473fc343ab14492bc6f813591e3cc40,
title = "DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy",
abstract = "Advanced glycation end products (AGEs) and their receptor (RAGE) play a role in diabetic nephropathy. We screened DNA aptamer directed against AGEs (AGEs-aptamer) in vitro and examined its effects on renal injury in KKAy/Ta mice, an animal model of type 2 diabetes. Eight-week-old male KKAy/Ta or C57BL/6J mice received continuous intraperitoneal infusion of AGEs-or control-aptamer for 8 weeks. AGEs-aptamer was detected and its level was increased in the kidney for at least 7 days. The elimination half-lives of AGEs-aptamer in the kidney were about 7 days. Compared with those in C57BL/6J mice, glomerular AGEs levels were significantly increased in KKAy/Ta mice, which were blocked by AGEs-aptamer. Urinary albumin and 8-hydroxy-29-deoxy-guanosine levels were increased, and glomerular hypertrophy and enhanced extracellular matrix accumulation were observed in KKAy/Ta mice, all of which were prevented by AGEs-aptamer. Moreover, AGEs-aptamer significantly reduced gene expression of RAGE, monocyte chemoattractant protein-1, connective tissue growth factor, and type IV collagen both in the kidney of KKAy/Ta mice and in AGE-exposed human cultured mesangial cells. Our present data suggest that continuous administration of AGEs-aptamer could protect against experimental diabetic nephropathy by blocking the AGEs-RAGE axis and may be a feasible and promising therapeutic strategy for the treatment of diabetic nephropathy.",
author = "Yusuke Kaida and Kei Fukami and Takanori Matsui and Yuichiro Higashimoto and Yuri Nishino and Nana Obara and Yosuke Nakayama and Ryotaro Ando and Maki Toyonaga and Seiji Ueda and Masayoshi Takeuchi and Hiroyoshi Inoue and Seiya Okuda and Shoichi Yamagishi",
year = "2013",
month = "9",
doi = "10.2337/db12-1608",
language = "English",
volume = "62",
pages = "3241--3250",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "9",

}

TY - JOUR

T1 - DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy

AU - Kaida, Yusuke

AU - Fukami, Kei

AU - Matsui, Takanori

AU - Higashimoto, Yuichiro

AU - Nishino, Yuri

AU - Obara, Nana

AU - Nakayama, Yosuke

AU - Ando, Ryotaro

AU - Toyonaga, Maki

AU - Ueda, Seiji

AU - Takeuchi, Masayoshi

AU - Inoue, Hiroyoshi

AU - Okuda, Seiya

AU - Yamagishi, Shoichi

PY - 2013/9

Y1 - 2013/9

N2 - Advanced glycation end products (AGEs) and their receptor (RAGE) play a role in diabetic nephropathy. We screened DNA aptamer directed against AGEs (AGEs-aptamer) in vitro and examined its effects on renal injury in KKAy/Ta mice, an animal model of type 2 diabetes. Eight-week-old male KKAy/Ta or C57BL/6J mice received continuous intraperitoneal infusion of AGEs-or control-aptamer for 8 weeks. AGEs-aptamer was detected and its level was increased in the kidney for at least 7 days. The elimination half-lives of AGEs-aptamer in the kidney were about 7 days. Compared with those in C57BL/6J mice, glomerular AGEs levels were significantly increased in KKAy/Ta mice, which were blocked by AGEs-aptamer. Urinary albumin and 8-hydroxy-29-deoxy-guanosine levels were increased, and glomerular hypertrophy and enhanced extracellular matrix accumulation were observed in KKAy/Ta mice, all of which were prevented by AGEs-aptamer. Moreover, AGEs-aptamer significantly reduced gene expression of RAGE, monocyte chemoattractant protein-1, connective tissue growth factor, and type IV collagen both in the kidney of KKAy/Ta mice and in AGE-exposed human cultured mesangial cells. Our present data suggest that continuous administration of AGEs-aptamer could protect against experimental diabetic nephropathy by blocking the AGEs-RAGE axis and may be a feasible and promising therapeutic strategy for the treatment of diabetic nephropathy.

AB - Advanced glycation end products (AGEs) and their receptor (RAGE) play a role in diabetic nephropathy. We screened DNA aptamer directed against AGEs (AGEs-aptamer) in vitro and examined its effects on renal injury in KKAy/Ta mice, an animal model of type 2 diabetes. Eight-week-old male KKAy/Ta or C57BL/6J mice received continuous intraperitoneal infusion of AGEs-or control-aptamer for 8 weeks. AGEs-aptamer was detected and its level was increased in the kidney for at least 7 days. The elimination half-lives of AGEs-aptamer in the kidney were about 7 days. Compared with those in C57BL/6J mice, glomerular AGEs levels were significantly increased in KKAy/Ta mice, which were blocked by AGEs-aptamer. Urinary albumin and 8-hydroxy-29-deoxy-guanosine levels were increased, and glomerular hypertrophy and enhanced extracellular matrix accumulation were observed in KKAy/Ta mice, all of which were prevented by AGEs-aptamer. Moreover, AGEs-aptamer significantly reduced gene expression of RAGE, monocyte chemoattractant protein-1, connective tissue growth factor, and type IV collagen both in the kidney of KKAy/Ta mice and in AGE-exposed human cultured mesangial cells. Our present data suggest that continuous administration of AGEs-aptamer could protect against experimental diabetic nephropathy by blocking the AGEs-RAGE axis and may be a feasible and promising therapeutic strategy for the treatment of diabetic nephropathy.

UR - http://www.scopus.com/inward/record.url?scp=84887322879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887322879&partnerID=8YFLogxK

U2 - 10.2337/db12-1608

DO - 10.2337/db12-1608

M3 - Article

VL - 62

SP - 3241

EP - 3250

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 9

ER -